While PCSK9 gain-of-function (GOF) mutations associated with elevated blood lipids, carriers of loss of-function (LOF) mutations benefited from low-density lipoprotein cholesterol (LDL-C) reduction by up to 28%, accompanied by an 88% reduced risk of coronary artery disease [1]. The gene discussed is PCSK9; the disease is coronary artery disorder.